



## Supplementary Materials



**A**



**B**



**Supplementary Figure S1. FGF1 anti-apoptotic activity depending on its nuclear localization in undifferentiated cells.** Confirmation of endogenous pool of FGF1 variants 48 h after transfection of (A) PC12 and (B) HEK-293 cell lines by Western blotting. 48 h post transfection cells were treated with 50  $\mu$ g/mL of etoposide in the presence of FGFR inhibitor, 100 nM PD173074. The viability of cells and the caspase 3/7 activity were determined after 48 h and 24 h using Alamar Blue reagent and ApoLive-Glo Multiplex Assay, respectively. Data were normalized to control values and presented as means  $\pm$  SD from three independent experiments. Statistical significance: \* $p \leq 0.05$ , \*\* $p \leq 0.01$ , \*\*\*  $p \leq 0.001$ .

**A****B**

**Supplementary Figure S2. Characteristics of the cell lines used in the study.** (A) Analysis of FGFR1-4 expression and endogenous FGF1 pool in selected cell lines. (B) Comparison of FGFR and downstream signaling cascade ERK1/2 activation after 15-min treatment with FGF1 (100 ng/mL) in the presence of heparin (10 U/mL).